Novo Nordisk's blockbuster drug is now a kidney disease fighter, threatening dialysis giants and reshaping the ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

The use of weight-loss injections has become near-normalised in today's society, but one singer is joining the charge in warning against their side effects, after she claims Ozempic has left her with ...